DelveInsight’s, Octegra-API Insights, 2015,report provides Octegra marketed details and API Manufacturers details across the globe along with the location. DelveInsight’s report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Octegra. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the Octegra Global sales forecasts data till 2016.
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.
A review of the Octegra based on information derived from company and industry-specific sources
Coverage of the Marketed data of the Octegra on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for drug with location details.
Patent Expiry Timeline and Exclusivity Details
Global Forecasted Sales Figure from 2012-2016
Qualitative and quantitative assessment of market space